Table 3 Literature review
References | Year | Age | Gender | Etiology | BCLC | Unresectable reason | Size maximum (cm) | Regimen | Cycles | Pathological | f/u | Cancer-free/drug free | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre | Post | Response | (month) | ||||||||||
[6] | 2021 | 68 | M | Non-viral | C | Rt adrenal meta | 72 | ND | ATZ/BEV → LEN | 4 | PR | 5 | + / + |
[7] | 2021 | 63 | M | ND | B | Tumor spread bilateral lobes | 15.5 | 17.2 | TACE → ATZ/BEV | 15 | PR | 19 | + / + |
[8] | 2022 | 79 | M | ND | C | PVTT | ND | ND | ATZ/BEV + TAE | 2 | PR | 5 | + / + |
[9] | 2022 | 77 | M | HBV | C | Rt adrenal meta, IVC invasion | 15.2 | 9.9 | ATZ/BEV | 9 | CR | 3 | + / + |
[10] | 2022 | 77 | M | Non-viral | C | Lung meta | 16.8 | 12.7 | ATZ/BEV | 7 | CR | 8 | + / + |
[11] | 2023 | 75 | M | ND | C | Peritoneal metastasis | 5.7 | 4.7 | ATZ/BEV + TAE | 15 | CR | 7 | + / + |
Our case | 2023 | 71 | M | Non-viral | A | Remnant liver volume | 12.5 | 7.3 | ATZ/BEV | 10 | CR | 12 | + / + |
Our case | 2023 | 72 | M | Non-viral | A | Remnant liver volume | 11.6 | 6.4 | ATZ/BEV | 7 | PR | 5 | + / + |